CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
July 2015—Biodesix launched GeneStrat, a targeted liquid biopsy mutation test for genotyping tumors of patients with advanced non-small cell lung cancer. Requiring only a blood draw, the test aims to offer a fast, minimally invasive alternative to a high-risk tissue biopsy or re-biopsy in patients with insufficient tissue. Blood test results are available within 72 hours, providing physicians actionable diagnostic information prior to making treatment decisions. GeneStrat is focused exclusively on the clinically actionable EGFR, KRAS, and BRAF mutations often used to guide targeted therapy treatment decisions. GeneStrat also captures the EGFR T790M mutation, which can be used for monitoring the emergence of the primary resistance mutation in the EGFR gene. The test uses the ddPCR platform to analyze cell-free tumor DNA and is highly concordant with tissue analysis.
Biodesix, 303-417-0500